ADDED
The number of outstanding shares of the Registrant s Common Stock as of March 10, 2026 was 33,401,553 .
Unstable global market and economic conditions may have serious adverse consequences on our business, financial condition and results of operations.
Even if any of our product candidates we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.
If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing an approved product.
Our pipeline is focused on treating chronic neuropathic pain and neuropathy.
Our Halneuron Na v 1.7 modulation program is intended to treat chronic and acute pain disorders.
Our recently licensed SP16 program is centered on a cell signaling molecule that has shown early promise in treating neuropathy and nerve damage.
The Halneuron program is a proprietary non-opioid Na v 1.7 analgesic program centered on voltage-gated sodium channel modulation, a mechanism known to be effective for reducing pain.
SP16 is the focus of a planned Phase 1b study that is fully funded through a research grant supplied by the National Cancer Institute, with patient enrollment projected to start in mid-2026.
In one review, chemotherapy induced peripheral neuropathy was found to commonly occur in 30 to 40% of patients.
REMOVED
The number of outstanding shares of the Registrant s Common Stock as of March 27, 2025 was 1,911,128 .
3 SUMMARY OF RISK FACTORS The following is a summary of the principal risks described below in Part I, Item 1A.
Even if Halneuron , IMC-1, IMC-2 or any other product candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.
If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing Halneuron , IMC-1 or IMC-2, if approved.
4 Risks Related to Our Dependence on Third Parties We currently rely on third-party contract manufacturing organizations, or CMOs, for the production of clinical supply of Halneuron , IMC-1 and IMC-2 and intend to rely on CMOs for the production of commercial supply of Halneuron , IMC-1 and IMC-2, if approved.
Risks Related to the Combination There is no guarantee that the Combination (as defined below) will increase stockholder value.
We may be required to settle shares of Series A Non-Voting Convertible Preferred Stock ( Series A Non-Voting Convertible Preferred Stock or Series A Preferred Stock ) for cash, which could have a material adverse effect on our business and financial condition.
The failure to successfully integrate the businesses of the Company and Pharmagesic (Holdings) Inc., ( Pharmagesic ) in the expected timeframe could adversely affect Dogwood s results of operations, financial condition, and future results.
Our pipeline is focused on two separate pillars: Na v 1.7 modulation to treat chronic and acute pain disorders and combination antiviral therapies targeting reactivated herpes virus mediated illnesses.
The proprietary non-opioid Na V 1.7 analgesic program is centered on our lead development candidate Halneuron , which is a voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain.